1. Home
  2. GERN vs NMFC Comparison

GERN vs NMFC Comparison

Compare GERN & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • NMFC
  • Stock Information
  • Founded
  • GERN 1990
  • NMFC 2010
  • Country
  • GERN United States
  • NMFC United States
  • Employees
  • GERN N/A
  • NMFC N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • GERN Health Care
  • NMFC Finance
  • Exchange
  • GERN Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • GERN 878.9M
  • NMFC 1.0B
  • IPO Year
  • GERN 1996
  • NMFC 2011
  • Fundamental
  • Price
  • GERN $1.27
  • NMFC $9.74
  • Analyst Decision
  • GERN Buy
  • NMFC Hold
  • Analyst Count
  • GERN 11
  • NMFC 3
  • Target Price
  • GERN $5.80
  • NMFC $11.33
  • AVG Volume (30 Days)
  • GERN 15.1M
  • NMFC 787.1K
  • Earning Date
  • GERN 05-07-2025
  • NMFC 05-05-2025
  • Dividend Yield
  • GERN N/A
  • NMFC 13.68%
  • EPS Growth
  • GERN N/A
  • NMFC N/A
  • EPS
  • GERN N/A
  • NMFC 1.03
  • Revenue
  • GERN $76,994,000.00
  • NMFC $371,666,000.00
  • Revenue This Year
  • GERN $208.83
  • NMFC N/A
  • Revenue Next Year
  • GERN $57.49
  • NMFC N/A
  • P/E Ratio
  • GERN N/A
  • NMFC $9.47
  • Revenue Growth
  • GERN 32386.92
  • NMFC N/A
  • 52 Week Low
  • GERN $1.19
  • NMFC $8.84
  • 52 Week High
  • GERN $5.34
  • NMFC $12.81
  • Technical
  • Relative Strength Index (RSI)
  • GERN 34.43
  • NMFC 39.61
  • Support Level
  • GERN $1.17
  • NMFC $9.09
  • Resistance Level
  • GERN $1.39
  • NMFC $9.56
  • Average True Range (ATR)
  • GERN 0.13
  • NMFC 0.42
  • MACD
  • GERN 0.01
  • NMFC -0.04
  • Stochastic Oscillator
  • GERN 21.74
  • NMFC 38.46

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

Share on Social Networks: